A Phase IIa, Safety and Preliminary Effects Study of WST11 (Stakel®) Mediated Vascular-Targeted Photodynamic (VTP) Therapy in Subjects With Choroidal Neovascularization (CNV) Associated With Age-Related Macular Degeneration (AMD)

Trial Profile

A Phase IIa, Safety and Preliminary Effects Study of WST11 (Stakel®) Mediated Vascular-Targeted Photodynamic (VTP) Therapy in Subjects With Choroidal Neovascularization (CNV) Associated With Age-Related Macular Degeneration (AMD)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 04 May 2015

At a glance

  • Drugs Padeliporfin (Primary)
  • Indications Age-related macular degeneration; Choroidal neovascularisation
  • Focus Adverse reactions
  • Sponsors Steba Biotech
  • Most Recent Events

    • 28 Apr 2015 Status changed from suspended to discontinued as per ClinicalTrials.gov record.
    • 24 Nov 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top